Heightened regulatory scrutiny could be a major blow for the online drug retailer, which just shelved its plan for a Wegovy ...
An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy ...
Hims & Hers Health (HIMS) stock saw it’s shares drop more than 30% during trading on Monday. The sharp decline was one of the steepest one-day drops in the stock’s history. HIMS shares fell after Novo ...
By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health on Thursday began offering a much ...
Virtual healthcare is rapidly evolving, led by Hims & Hers Health, Inc. HIMS and Teladoc Health, Inc. TDOC. HIMS offers a consumer-centric, subscription-based platform providing access to personalized ...
Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...
HIMS is upgraded to a speculative Buy after the steep correction, with the cheaper valuations offering a much-needed, improved margin of safety. Robust subscription/ARPU growth, international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results